Quanbo Zhou

Dr. Quanbo Zhou


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2023 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
BZBin Zhang
Bin Zhang
XGXiaofeng Guo
Xiaofeng Guo
LHLeyi Huang
Leyi Huang
YZYuting Zhang
Yuting Zhang
ZLZhiguo Li
Zhiguo Li
QZQuanbo Zhou
Quanbo Zhou

29 March 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
LWLusheng Wei
Lusheng Wei
QLQing Lin
Qing Lin
YLYanan Lu
Yanan Lu
GLGuolin Li
Guolin Li
LHLeyi Huang
Leyi Huang
QZQuanbo Zhou
Quanbo Zhou
Cancer-associated fibroblasts (CAFs) contribute to malignant progression and chemoresistance in pancreatic ductal adenocarcinoma (PDAC). However, little is known about the underlying mechanism. In this study, we investigated the potential role and mechanisms of activating transcription factor 4 (ATF4) in CAFs-induced malignancy and gemcitabine resistance. We demonstrated that ATF4 is overexpressed in PDAC and associated with a poor prognosis. Silencing ATF4 expression decreased proliferation, colony formation, migration, gemcitabine sensitivity, and sphere formation. Subsequently, we revealed that CAFs secrete TGF-β1 to upregulate the expression of ATF4 in PDAC cells via the SMAD2/3 pathway and induce cancer progression, cancer stemness, and gemcitabine resistance. Furthermore, we demonstrated that ATF4 directly binds to the ABCC1 promoter region to activate transcription. In summary, these data demonstrate that CAFs contribute to malignancy and gemcitabine resistance in PDAC by upregulating the expression of ATF4 via the TGF-β1/SMAD2/3 axis and highlight that ATF4 is an attractive therapeutic target for combating gemcitabine resistance in PDAC.

1 January 2021 in International Journal of Biological Sciences
Verified
Journal Article
Open access
YZYu Zhou
Yu Zhou
SLSiyang Liu
Siyang Liu
CLChao Liu
Chao Liu
JYJiabin Yang
Jiabin Yang
QLQing Lin
Qing Lin
RCRufu Chen
Rufu Chen
Aims: Using Single-cell RNA sequencing (scRNA-seq), we explored the spatiotemporal heterogeneity of pancreatic neuroendocrine tumors (pNETs) and the underlying mechanism for malignant progression.

9 March 2022 in Oncogene
Verified
Journal Article
Open access
PDF file
XZXiang Zhang
Xiang Zhang
SZShangyou Zheng
Shangyou Zheng
CHChonghui Hu
Chonghui Hu
GLGuolin Li
Guolin Li
HLHongcao Lin
Hongcao Lin
QZQuanbo Zhou
Quanbo Zhou
The tumor stroma of pancreatic ductal adenocarcinoma (PDAC) is characterized by an abundant and heterogeneous population of cancer-associated fibroblasts (CAFs), which are critically involved in chemoresistance. However, the underlying mechanism of CAFs in chemoresistance is unclear. Here, we show that CAFR, a CAF subset derived from platinum-resistant PDAC patients, assumes an iCAF phenotype and produces more IL8 than CAFS isolated from platinum-sensitive PDAC patients. CAFR-derived IL8 promotes oxaliplatin chemoresistance in PDAC. Based on long noncoding RNA (lncRNA) profiling in tumor cells incubated with CAF-CM, we found that UPK1A-AS1, whose expression is directly induced by IL8/NF-kappa B signaling, functions as a chemoresistance-promoting lncRNA and is critical for active IL8-induced oxaliplatin resistance. Impressively, blocking the activation of UPK1A-AS1 expression increases the oxaliplatin sensitivity of tumor cells in vivo. Mechanistically, UPK1A-AS1 strengthens the interaction between Ku70 and Ku80 to facilitate nonhomologous end joining (NHEJ), thereby enhancing DNA double-strand break (DSB) repair. Clinically, UPK1A-AS1 expression is positively correlated with IL8 expression, a poor chemotherapeutic response and a shorter progression-free survival (PFS) time in advanced PDAC patients. Collectively, our study reveals a lncRNA-mediated mechanism of CAF-derived paracrine IL8-dependent oxaliplatin resistance and highlights UPK1A-AS1 as a potential therapeutic target.

10 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYanfen Zheng
Yanfen Zheng
XLXingyang Li
Xingyang Li
SDShuang Deng
Shuang Deng
HZHongzhe Zhao
Hongzhe Zhao
YYYing Ye
Ying Ye
ZZZhixiang Zuo
Zhixiang Zuo
N6-methyladenosine (m6A) modification of gene transcripts plays critical roles in cancer. Here we report transcriptomic m6A profiling in 98 tissue samples from 65 individuals with pancreatic ductal adenocarcinoma (PDAC). We identify 17,996 m6A peaks with 195 hyper-methylated and 93 hypo-methylated in PDAC compared with adjacent normal tissues. The differential m6A modifications distinguish two PDAC subtypes with different prognosis outcomes. The formation of the two subtypes is driven by a newly identified m6A regulator CSTF2 that co-transcriptionally regulates m6A installation through slowing the RNA Pol II elongation rate during gene transcription. We find that most of the CSTF2-regulated m6As have positive effects on the RNA level of host genes, and CSTF2-regulated m6As are mainly recognized by IGF2BP2, an m6A reader that stabilizes mRNAs. These results provide a promising PDAC subtyping strategy and potential therapeutic targets for precision medicine of PDAC.

19 September 2023 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
GWGuandi Wu
Guandi Wu
JSJiachun Su
Jiachun Su
LZLingxing Zeng
Lingxing Zeng
SDShuang Deng
Shuang Deng
XHXudong Huang
Xudong Huang
JZJian Zheng
Jian Zheng